<SUBMISSION>
<ACCESSION-NUMBER>0000950134-05-006286
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050328
<ITEMS>2.02
<ITEMS>9.01
<FILING-DATE>20050330
<DATE-OF-FILING-DATE-CHANGE>20050330
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>BIOSANTE PHARMACEUTICALS INC
<CIK>0001023024
<ASSIGNED-SIC>2836
<IRS-NUMBER>582301143
<STATE-OF-INCORPORATION>WY
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-31812
<FILM-NUMBER>05711447
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>BEN ABRAHAM TECHNOLOGIES INC
<DATE-CHANGED>19991027
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c93671e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>


<P align="center" style="font-size: 10pt"><HR size="1" noshade width="26%" align="center" color="#000000">


<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>


<P align="center" style="font-size: 12pt"><B>Current Report<BR>
Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B>


<P align="center" style="font-size: 10pt"><HR size="1" noshade width="26%" align="center" color="#000000">



<P align="center" style="font-size: 10pt">Date of Report (Date of earliest event reported):<BR>
<B>March&nbsp;28, 2005</B>


<P align="center" style="font-size: 24pt"><B>BIOSANTE
PHARMACEUTICALS, INC.</B><br>
<div align="center" style="font-size: 10pt">(Exact name of registrant
as specified in its charter)</div>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>1-31812</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>58-2301143</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or Other Jurisdiction of
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer Identification</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">Incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Number)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>111 Barclay Boulevard</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Lincolnshire, Illinois</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>60069</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of Principal Executive Offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><B>(847)&nbsp;478-0500</B><BR>
(Registrant&#146;s Telephone Number, Including Area Code)



<P align="center" style="font-size: 10pt"><B>N/A</B><br>
(Former Name or Former Address, If Changed Since Last Report)


<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-family: Wingdings 2">&#163;</FONT> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-family: Wingdings 2">&#163;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-family: Wingdings 2">&#163;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-family: Wingdings 2">&#163;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><B>Section&nbsp;2 &#150; Financial Information</B>



<P align="left" style="font-size: 10pt"><B>Item&nbsp;2.02. Results of Operations and Financial Condition</B>.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;28, 2005, BioSante Pharmaceuticals, Inc. publicly announced its key achievements and
financial results for the year ended December&nbsp;31, 2004. For further information, please refer to
the press release attached hereto as Exhibit&nbsp;99.1, which is incorporated by reference herein.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information contained in this report and the exhibit hereto shall not be deemed to be
&#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, and shall
not be incorporated by reference into any filings made by BioSante Pharmaceuticals, Inc. under the
Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by
specific reference in such filing.


<P align="left" style="font-size: 10pt"><B>Section&nbsp;9 &#150; Financial Statements and Exhibits</B>



<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<I>Exhibits</I>.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
    <TD width="23%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Exhibit</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Description</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD valign="top" align="center"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release issued March&nbsp;28, 2005</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="center" style="font-size: 10pt"><B>SIGNATURE</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>BIOSANTE PHARMACEUTICALS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Phillip B. Donenberg
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Phillip B. Donenberg&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left"><I>Chief Financial Officer, Treasurer and Secretary</I>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">Dated:&nbsp;&nbsp;March&nbsp;28, 2005</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><B>BIOSANTE PHARMACEUTICALS, INC.</B>



<P align="center" style="font-size: 10pt"><B>FORM 8-K</B><BR>
<U><B>Exhibit&nbsp;Index</B></U>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">

<TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Exhibit<br>No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Method of Filing</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" align="center"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release issued March&nbsp;28, 2005
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Filed herewith</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c93671exv99w1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="right" style="font-size: 10pt">Exhibit&nbsp;99.1

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&nbsp;</B></TD>
</TR>

<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD rowspan="6" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="c93671biosantelogo.gif" alt="(BIOSANTE LOGO)">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
</TR>
<TR valign="top">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD align="left" valign="top"><B>BioSante Pharmaceuticals,
Inc.</B><BR>
111 Barclay Boulevard<BR>
Lincolnshire, Illinois 60069<BR>
www.biosantepharma.com
</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>

    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="left" style="font-size: 10pt"><HR size="2" noshade width="100%" align="LEFT">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>FOR IMMEDIATE RELEASE</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>Amex: BPA</B></TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><B>BioSante Pharmaceuticals Announces 2004<BR>
Key Achievements and Financial Results</B>


<P align="left" style="font-size: 10pt"><B>LINCOLNSHIRE, Illinois (March&nbsp;28, 2005) </B>&#151; BioSante Pharmaceuticals (Amex: BPA) today
announced key achievements and financial results for the year ended December&nbsp;31, 2004.


<P align="left" style="font-size: 10pt">&#147;We continued to make important progress throughout the year in our late stage hormone therapy
clinical programs, and CAP nanotechnology,&#148; commented Stephen M. Simes, BioSante&#146;s president and
chief executive officer. &#147;We expect our efforts to result in a new drug application filing with
the FDA for Bio-E-Gel&#153; and the initiation of our Phase III development program for LibiGel&#153; in
2005.&#148;


<P align="left" style="font-size: 10pt">Highlights for the last 15&nbsp;months include:



<P align="left" style="font-size: 10pt"><U>Hormone Therapy Achievements</U>



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="5%" nowrap align="left">&#149;&nbsp;&nbsp;</TD>
    <TD>Completed enrollment in our pivotal Phase III clinical trial of Bio-E-Gel (bioidentical
estradiol gel).</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="5%" nowrap align="left">&#149;&nbsp;&nbsp;</TD>
    <TD>Reported positive results of the completed Phase II clinical trial of LibiGel
(bioidentical testosterone gel) for treatment of female sexual dysfunction (FSD)
significantly increasing (238%) the number of satisfying sexual events.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt"><u>CAP Nanotechnology Achievements</u>



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="5%" nowrap align="left">&#149;&nbsp;&nbsp;</TD>
    <TD>Product developments:</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="5%" nowrap align="left">&#151;&nbsp;&nbsp;</TD>
    <TD>Received notice of allowance from the European Patent Office (EPO)&nbsp;accepting
BioSante&#146;s patent application for the manufacturing process of the company&#146;s unique
calcium phosphate nanoparticles (CAP).</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="5%" nowrap align="left">&#151;&nbsp;&nbsp;</TD>
    <TD>Positive pre-clinical results for intranasally administered BioVant&#153;/anthrax
vaccine, compared to an Alhydrogel/anthrax vaccine or the antigen alone.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="5%" nowrap align="left">&#151;&nbsp;&nbsp;</TD>
    <TD>Positive results in animal models for the sustained-release delivery of
therapeutic proteins, including long-acting buccal delivery of insulin.</TD>
</TR>

</TABLE>


<P align="center" style="font-size: 10pt">-more-



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="5%" nowrap align="left">&#149;&nbsp;&nbsp;</TD>
    <TD>Current product development agreements:</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="5%" nowrap align="left">&#151;&nbsp;&nbsp;</TD>
    <TD>U.S. Navy: Cooperative Research and Development Agreement (CRADA)&nbsp;for
evaluation and development of a malaria vaccine.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="5%" nowrap align="left">&#151;&nbsp;&nbsp;</TD>
    <TD>U.S. Army: CRADA for evaluation and development of non-injected biodefense
vaccines including anthrax, ricin, staph and bubonic plague.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="5%" nowrap align="left">&#151;&nbsp;&nbsp;</TD>
    <TD>DynPort: U.S. Department of Defense subcontract for evaluation and development
of a non-injected anthrax vaccine.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt"><U>Financial Achievements</U>



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="5%" nowrap align="left">&#149;&nbsp;&nbsp;</TD>
    <TD>Raised new capital in a $17.7&nbsp;million ($16.4&nbsp;million net of transaction costs) common
stock/warrant placement.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="5%" nowrap align="left">&#149;&nbsp;&nbsp;</TD>
    <TD>Closed the year with $17.3&nbsp;million in cash, cash equivalents and short-term investments.</TD>
</TR>

</TABLE>

<P align="left" style="font-size: 10pt">BioSante incurred a net loss of approximately $12.0&nbsp;million or ($0.70) per share for the year ended
December&nbsp;31, 2004, compared to a net loss of $6.0&nbsp;million or ($0.54) per share for the same period
in 2003. The increase in the net loss is largely the result of increased research and development
expenses incurred primarily as a result of (i)&nbsp;completing the Phase II LibiGel trial, and (ii)
conducting the Phase III Bio-E-Gel trial. The company&#146;s cash, cash equivalents and short-term
investments as of December&nbsp;31, 2004 were approximately $17.3&nbsp;million, compared to $9.1&nbsp;million at
December&nbsp;31, 2003.



<P align="left" style="font-size: 10pt"><B>About BioSante Pharmaceuticals, Inc.</B>


<P align="left" style="font-size: 10pt">BioSante is developing a pipeline of hormone therapy products to treat both men and women. These
hormone therapy products are gel formulations for transdermal administration that deliver
bioidentical estradiol and testosterone. BioSante&#146;s lead products include Bio-E-Gel<SUP style="font-size: 85%; vertical-align: text-top">&#153;</SUP>
(bioidentical estradiol gel) for the treatment of women with menopausal symptoms, and
LibiGel<SUP style="font-size: 85%; vertical-align: text-top">&#153;</SUP> (bioidentical testosterone gel) for the treatment of female sexual dysfunction
(FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5
billion. The company also is developing its calcium phosphate nanotechnology (CAP)&nbsp;for novel
vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery
systems. Additional information is available online at <U>www.biosantepharma.com</U>.



<P align="left" style="font-size: 10pt"><I>This news release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. The statements regarding BioSante contained in this press release
that are not historical in nature, particularly those that utilize terminology such as &#147;may,&#148;
&#147;will,&#148; &#147;should,&#148; &#147;likely,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;estimates,&#148; &#147;believes&#148; or &#147;plans,&#148; or
comparable terminology, are forward-looking statements. For example, our statement regarding the
expected timing of the filing of a new drug application with the FDA for Bio-E-Gel&#153; and the
initiation of pivotal studies of LibiGel&#153; is a forward-looking statement. Forward-looking
statements are based on current expectations and assumptions, and entail various risks and
uncertainties that could cause actual results to differ materially from those expressed in such
forward-looking statements. Important factors known to BioSante that cause actual results to
differ materially from those expressed in such forward-looking statements are the difficulty of
developing pharmaceutical products, obtaining regulatory and other approvals and achieving market
acceptance, and other factors identified and discussed from time to time in BioSante&#146;s filings with
the Securities and Exchange Commission, including those factors discussed on pages 19 to 31 of
BioSante&#146;s </I><I>Form 10-KSB</I><I>, which discussion also is incorporated herein by reference.</I>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="left" style="font-size: 10pt"><B>For more information, please contact:<br></B>
Phillip Donenberg, BioSante Pharmaceuticals, Inc.; (847)&nbsp;478-0500; donenber@biosantepharma.com<br>
Ritu S. Baral, The Trout Group LLC; (212)&nbsp;477-9007 ext 25; rbaral@troutgroup.com<br>
Daniel Budwick, BMC Communications; (212)&nbsp;477-9007 ext 14; <U>budwick@bmccommunications.com</U>




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c93671biosantelogo.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c93671biosantelogo.gif
M1TE&.#=AR0!1`/<```````$!`0("`@,#`P0$!`4%!08&!@<'!P@("`D)"0H*
M"@L+"PP,#`T-#0X.#@\/#Q`0$!$1$1(2$A,3$Q04%!45%186%A<7%Q@8&!D9
M&1H:&AL;&QP<'!T='1X>'A\?'R`@("$A(2(B(B,C(R0D)"4E)28F)B<G)R@H
M*"DI*2HJ*BLK*RPL+"TM+2XN+B\O+S`P,#$Q,3(R,C,S,S0T-#4U-38V-C<W
M-S@X.#DY.3HZ.CL[.SP\/#T]/3X^/C\_/T!`0$%!04)"0D-#0T1$1$5%149&
M1D='1TA(2$E)24I*2DM+2TQ,3$U-34Y.3D]/3U!04%%145)24E-34U145%55
M55965E=75UA86%E965I:6EM;6UQ<7%U=75Y>7E]?7V!@8&%A86)B8F-C8V1D
M9&5E969F9F=G9VAH:&EI:6IJ:FMK:VQL;&UM;6YN;F]O;W!P<'%Q<7)R<G-S
M<W1T='5U=79V=G=W=WAX>'EY>7IZ>GM[>WQ\?'U]?7Y^?G]_?X"`@(&!@8*"
M@H.#@X2$A(6%A8:&AH>'AXB(B(F)B8J*BHN+BXR,C(V-C8Z.CH^/CY"0D)&1
MD9*2DI.3DY24E)65E9:6EI>7EYB8F)F9F9J:FIN;FYR<G)V=G9Z>GI^?GZ"@
MH*&AH:*BHJ.CHZ2DI*6EI::FIJ>GIZBHJ*FIJ:JJJJNKJZRLK*VMK:ZNKJ^O
MK["PL+&QL;*RLK.SL[2TM+6UM;:VMK>WM[BXN+FYN;JZNKN[N[R\O+V]O;Z^
MOK^_O\#`P,'!P<+"PL/#P\3$Q,7%Q<;&QL?'Q\C(R,G)R<K*RLO+R\S,S,W-
MS<[.SL_/S]#0T-'1T=+2TM/3T]34U-75U=;6UM?7U]C8V-G9V=K:VMO;V]S<
MW-W=W=[>WM_?W^#@X.'AX>+BXN/CX^3DY.7EY>;FYN?GY^CHZ.GIZ>KJZNOK
MZ^SL[.WM[>[N[N_O[_#P\/'Q\?+R\O/S\_3T]/7U]?;V]O?W]_CX^/GY^?KZ
M^OO[^_S\_/W]_?[^_O___R'Y!```````+`````#)`%$`0`C_`!L(=""PH$&#
M!`LF/(B0X4"&#A(N=$B18,0&%C%2W,BQH\>/#B^"'%E1(X-_*".*/&@CG\M\
M^*8QT:%C1XX<.F[FV./LI4M\WD84!-)&C1HV=20H!#EQX0.?]V`.JW/DALZK
M.''F[&'AX$2."S,V##GV:PIP^:+>P[51XL.Q&T^B7,JP)=2?/O'9PP?3);UB
M7!@<!.4S'XV"7_"IQ2<NA>"!#%20@QDU'Y['5OBFA:GY[F:^]_"1$X+0P6.*
M#!A$>:?XY5MM/G\]$$R[`:[.]Y@<3/'-9>A;CP5;9-67KZ74$..B_/?UK8W*
M42^5;,"`5'%\\Z8,]%38!D8&\Q1'_VV7Q"&#)GFMA24ID%E4OOB<"3S2SB>Z
MTZ<;:,*;SWO!;3X-\P!#4<3CTQU+J?`-:/D`DQ]!$D15CTO/4(=<:A@BQY!<
MS&E4D4H@ACB02@+E5QI&7[GEP`,ZK!$'''"\L)*'$H5HXT4X=F21B#>*J!"(
M#=6(HHI>[2A2<S^2..2&RW7T`!A8:)$%%T>@N!$+46:AY15="60#%UIF`<:`
M&'5QA99:/-&41@Y(&683,[*70Q=:2,D%%`(]`$6=9VJ!07,.?*E%E&,:Y`28
M66AA1',85!'F%R@<]$`4B6+!!1`F-@"!&&%JD80%#X0JJJ@00-`<ATY^(66=
M7'3!Q1541/^Q1!)'*)$$$3?Y0,03.7SU9:):%#J0%X,.^H4-9.9Y0YW%:D%B
M#U]DL<69EGXAQA=@9*NMME-`\4,(#*R))(H/"/&%I8E6@5`37:!YQ`,KPOL`
M"%7PJ848*4:Q*A<^9-K`!IPFF@45&L#K(5P%H4H61F`@R@450?SP`Q`]2`P$
M$$&(66D642*QT`M43"'%%%H8S-Y&3W"!!18<8P%&%D1<+//,$P/A`\8;G*SS
MR0\\8>>E.W^D,%@')^>16'2]]="X1"-L=-%OQ;G4>EX5J2-3'TG-T=!D<::9
M6IOE<\X#E=&XAF)M-&#"-?BT'9K8BK'1P$\[XD3"W"XIE(-+LBC_U(9B:ZB-
M36M]F>-2&VGA,V+1G?456MMGM_W6V?G(?0/?BPO4EP./<V2"-7U19D[<FS<0
MBF_7X8-.#DRB=`_8A<4N^^RTUV[[[;CGKOONO/?NN^SP@;8<D!O6TO9+L(<-
M'5_H<.'5Z3_A<X/2.V=D1#/PA3Y[X_G0$?3W.J*`UO&XA`L^]0(-C[1!=G%&
MC,E(FS9*8=UT8)$GE;4]_4I<=$9XV]EK@UOV4!AW<`!K$%G`2[BW0,[D@Q-D
MR@B`:)>]>\3C"@41'P#A\YZ?1,4.-!I$]OZG&/BHH74=@IJ7H'(/"S%@`2],
MS0(ZX!NWX0,-,`Q7*;I#G2>4,"J\>%!"_Q@0"\U@1PKF88"\(A*J>'6@"L0(
MFTLFD;`DG(-PE4D<='QR&(ULXWCY$!!#GA"/SB#((&?QR2T<HH<:2A&,"\1'
MX`["-8?X`'6+>1L<'?@2>I1`(=SA8EB0`<#K1`^,Q7B+"Z18F"PB+W$_.:-`
M@(&Z[%&FD'STCT`FZ!(Q'J1`!\H/`P8!E1+R)1`:P8+V$H>;S;@!A4A*R)-6
M=04NM*H+N.S"%W#YA2VPK%)U<H%!<-"N.H5A(AH(`[`2U84D_,`'3-C"H*@U
MAB[EJ0RVS*8V;VE+5Q5K9;9<U$":L+(L0>QB0;C8Q'S&,3$EJP&'DM(6BL"H
M*OS2"Y$Z2!!45O^L+$`A8D/00$%^P(5!86$+7YB"$Y2P!"4P5`E,D$+.Z-@D
M].4I#%**DA-`L($.=&`#'`"I!C1`@UH*K$X3^966A%4!-ZV,"!PA`C"K8$V)
M2$`#*V!!3G>:TQ/(8`EAB-(5I`2&/[)I!#^``A6NE2TO8"L,NVSG%80ED$.A
M29P':=2C\EF026G)4D-PR`C.%:6558$*5J!"%:I@A;9680I=\``*G02E=F+U
M2@+3$A4@4)`;@&&773##FAH@`RGT,J-VV@(8H`"#KY@@6G7"0A28!A>D,0"P
MN<0L+UW5A!VXI2!1^.MF,>O4+U2A""DPR`.H@$LO`&ME6O@"8,.06H3_L.`(
M5/CK%VZI2UV:X6X4G0M$$@(!-,A6MMG2Y5_!`-4OA`$,6KB"$GP@`B+1``M4
M4&L7WEF]I34@`S](`A6T$(8NZ/:XZ-4M&,30@O.Y5VD.J`*VO%`&(PCGO0:I
M8]0:4)E8,(0-+WE#Y]9`"EC(XA%>N*\#V@`)6<PB%K2`A2`J@)$UK*$-#UA#
M+&0ABB4(A`UM$&`;:!&+6`BP`3>0!(E!L06$L"$2L)B%+&0!BT!06&UK(#$L
M-AP)-DB$!&N@<8EI\0@,-Z`-%SY(#D"L@S9(@B_6"+&4!1)BN3D`R#..A8$C
M<>*!K*'!)99%+`)!`0>X+2%<",2,9SR+4'0Y_[C_F`[>\@&+A>%-<1Y:@TL"
MQP4/VB,?D8A<VMRFPN,99&_X\&]!`)R/M&T!CO<H<E36\`!1N(TS]S!'VC`2
MBA*RTAJZ:4`@Q-,V603B<`+I<]C,X;P&$-H!HV@-&-$QQRY<DB^08`-?])RW
M!I2`;:7,1RBX2YTF8<C.)<I0AEQX7[H0A#;(H>S1%@9M95O[0BK$+_B.;;[W
M3H1#Q&-)',&H1\(5!A_UP,&(N/,>?&B2:5I3&@O>$;U+4I`_(,RVMLF")!6`
MPXBV4'#2QB5M_8H;=9Y<'W4R$<=XX`E"(@B!Q$F@\(%\X1/6\(8WOC&),B")
M`7.XBPRF79(0@$#B*/]/>0A&,!OAQ&D#(XBXRE%N`0W1J`,AZ,`3RK%`84@`
M!!\0`0F(/40'C"`$,C_Y"$I`;'!;M`'M:QLS;G!R$)Q\Y1\(01[`D<6VR:#;
MG9!B#12"A'F$KC7.*,8C_2*%QVB@@?B`QQ],L^QE4X<B"S#B[/28EGMDP2V<
MM&$#^1@,@;R@C(]#GJ=AXH>!6*+=P*-,/EX)9\I&W8WG3KQ+Y.&,=SI`%#S$
MB/_`88*#R1)U^0`'<#%B!P9AWI%X.1XU)'`J%S*[`9?0NR8;P(VP)1RT\<BB
M)`7B;Y^4STH":<'9C?%L?SE_>"HD2-3O(<84"60!0_@,3$B#D4"^Q#NJ`2/_
M/A*9'`9$(_'SH,+3/R005,11&P79A1N/!YK@Z=X@G`PCL4'YDCMTNP$JX`TU
M%'!BP0!X@$EY<6D.)#=PUA$,`!I1`0PRX`%6!W02YP%:QW77D0T"U7T\1!`1
M\!F*@0H,\0IOPQD\P"9L4%KH=5Q=4%[.%0C0,`^0AP]E(!!38':M,0XF8A&=
M\#7]@7\!LG\&\A+Y5A`<,#B+`0:9TD;U%PVSD43F45%:<P.6%#NPYQ//8`)-
M$79XT45OX0B-LT?X,`@SX@`PP$"R\SJ/A`YJ0B,,X`-[P4!9N!EC5Q"PX3;%
MP%<3049@Y'\TT@`8((#<@P_YEA`?(`M;Y#@+=$(-_ZAO$``&6Y`%0W52E3@H
M'"--'*,%5-(0.*`R66`%A3(1)#!>7X6)86(I56!4/S(&9Q(FL-@IG9(E61`%
M$^`52H`F:&(%`K,RO<@Q5`5/*F,I1N`06L4R79!:7X$#J_)-EL)5&*$$];(R
M0\4R_,0R8!`"<U42D9A17$`$2E(T'.`H+9,F"Z%2[E0B(M`%OZ0%5>!Y#?``
M4E`G7W4"IA<2/N(`0%!,6O(%+D`0C>(F6P`$F5,0@E(GP6A5B7)7!:%5_0B-
M\1@%Y30ESM8`0@`F+",&%U`UG_6(X]*-5[42S?$#OQ0E4'".B)*.#7`!L0A3
M&S$$D84%5;"15*,C$4$I8?_2!4]0$"D069MH*:Q24/2840F)*(I23ULE*?H2
M)5WP`PZ!`JKR6EF"6"<5!MKXB$;#`$P@)55P!4/E)NW$,M'E2RM3!,3V*X22
M+->X!5109G=G$!#@)G62!`MQ`?,(BV`9BZ>()EP0`_I6$3@@38,"!A'@(?'$
MB?3$$!K0CET`D5Z5*%P0!!11!N6D!7A"/91E<`\!`>?"+.!H-03Q`:_(,E@P
M<@5!`T+I3F%!!.QX4AQ3C;!E*4JP-&(`6UGP!;TB;>NG!5L@E,Q24,!D4%P@
M!9_5!,`9EGPB5'PB!J6'$?K"B:39,KZ)3P4!`58PE5<PB<P"+%P@!B*PC1OQ
M)&+_.4_PU@!&T#)18@4=F#1/,R+AYA`6(`8&%5NKIYNZN6\DX56#P@5.>9\G
MHYE=I2JVF5&Z"$R\>%),<!J!XEI#!0851Q)A\0.N52EE95#E=*&58@6-B9\Z
M\Q4]DU%=()D<6FS"E355,S7WV)Z@V9X/^I='TQ3Q`U\(,U@D-Z.8>8_^F5\5
M=:("84F:]Q/HX`")\W_(9B7ER9[EV9')H:0YRJ0#00%%T04001E7TQ8%0:5R
M-H4ENA$OH6@*H6MI\3<`=`T;A@Z@47J1X!+'D!6V%J9S`T#&(`O',PJN]A+%
M0`O'P!\SA@TOT2N/T#;'H`,XL`.JUFC&H!DS!@MF&AJ!_V,,?,,$.;`#:X`.
M+K$WO380B',/;("G+G$.&Q9C=>9J?-$`QX"H,W9%8>H`:8H/QG`3.Z`%FO$W
M:2$0E)H/:U`3.8`XBL$Z6(DPFN&E1J(2H'$D;1`5:>,;81%%]S!HHUHU\'%H
M+J%H$?$WRWIG$Z%VMIH.;?,)3&`3;3`ZMMH`VHH/H280D3!C2S`X^``*.Y`3
M@-`7<K,#4!81BI@/.C`W4=$`J`H*G74#;7`.>X:O^1!!#G"HMEI"`K%AM,"K
M&,$$,.&E";.C(SJQ%%NQ%GLR7P&@8O%91_J73@H^(HDU2GJQ16JEY_-M3?*@
M*)`'@+"(G@$3ZR`-CN`Q4>,`,O_8#,W`#-JP`ASJ`#&P",#`#ORQAO3W!R1K
MHH8'#YAF#/NV$.`6CAEQ`I!F.VKQ.'W0;0[@?2X!AMUE$&NP%S6DAGEQ@L-W
MM$:3$&D$0`'GH@AD$NJC->WC$O;@#NVP#N[`#NYPMW?[9T84%;Y@$)I`#_0P
M#_1P#UR[L2KJ%;*`1S!A#^^P#NP0N9(KN7>+M^P@!^PY$CE2DPO#N2O`=9H!
M'#]2-#3J$4\+MWDA#,1V=PS0`>&P0/?@#DB`(M;F-,R&;3OR$#C`B/B`"U$8
M%T+#'K5G'C%Z$"+PNC]1"YG"L3KC=!L1M_E0#`1''83P&??P#N5Z"@JH;E_A
M`8L;/&__$QJM@`$,T7JHLPX=D+GJ:Q!Y=SM\D0HP0!%7)+;',PUOD"P.P`)"
M"TE&Y#^-]Q80P`;-\$:01WDZNJ4.<7G!P#0,$`%H$3;`8!">P$'X`(8140=;
MY$A\AP__*Q!0<';X0`;"2T=[%#N%%!40NTEU.&XN$0].V0"\$3S%X4;W8`?F
MXP"M@'J/,T)\D0;@21%1!T#MUDH[?`_S\`>/$1&@X$@VX'*&TQGH``:L6P;E
M0&KY,`\/\<`,XGI8B`_!0`I!L+H2=W59]P$?,`(CT`2O``]8Q`Q+`1N;L0UN
M8%Y?X`5^\`Q@2S?)Q@`;P`W!(PLY9',T\#5Z`0UM,`-9%P)9_Z=T39>RJ#NT
MD,1*E40/CQ`DG%`8A^$`"S`.??L&YH$'4I0,;/()L"MKC%1#E6$/5E"R'O(`
MN!!'/%L0V>`3QQ!!!2$&L#,'!\,;/K&V=$$/&S0/0N%=@5AY3'-Y^``.&M<-
MWP`.W_`-&H<.B<<7ZK`491!Z,M!W,($,<<');[,.!)D1#F`&N^`-Y4`.Y6`.
MZHP.YG#.YP`//YH/ZH<00>`)RP"$'>1`H;%[$Q05G@094&`@[W$9'I)&+T&`
M;]$%K1$:[Q`-S)"SR[`,S2#1S)`,UZ`NO9K`L;.Z'J*`:P$O$:&U0=@`2G!I
M^-`+24Q'L^!`\;"3\187#W`\[W$,!?\1`_2P2N?F/VWC'P3Q19I!#'QH$*MQ
M@D<H$`;-%Z+[%@<(>_Z3@&@`2X""$9?WSPIG"`WD<-L1>F2C1]:@%`KG/]VP
M>DA;$//C$]N`$23`=?FS"TF`<E87`B9`'`O$ST-(($7H$B`4M0^<%KF@H`+Q
M`]9K#JC0":#P"9[P"9U@V(C-"B)ZP''&$;N[0!X`0^S)`!6`O(5SKQ[H$]-#
M'=;A$[M`$;Y@2:2`']=V;=<W!F&+#Z*`@W>=#\H;$NSV$W3]$O\,?#YQB`*Q
M`N.`%_'0;!IA.'U1#]_)HRH$H%?:08)7;Y$</;Z<M85QAP(!"5A("%%P!([0
M;I4A"J<1`Z?_3#NAL1@NL0X=.`+=H'C%T`5.T`10$`5/X`16T`LG7-N=1(0'
M4C3&H-SX0`I7\`12<)67W4#W\`R9P`B.<."0X`B/@`F=[=BQM$(\3'_\X3]1
MX6$2(=(\/1#"('F99Z?<]0)BZ[[Y<`D2P0"7(^%><TA,+(2V;=_]!Q&]/3O#
MUS\V).&PXXB.C3X)X0+=X`W<T`U`SLQ`_@U#'N3&4`I?H`$]V`"+X`W;X`W:
M\`W"E+$.(`C78`[L\`[OT`[E<`V-L!X)@0)$'N1D'N3/#.3;<`V<4`=BS286
MT0:RT`W<X`UH/N9`[N/<P`W;,.63).=SW@K$=@330.9H\"`%(06?_Q#D/]X-
MA>YL7>`)R/#CW!#E/[X-VM!B'LF1Q75>Q^4%VN(%GHXMK\($/G"5;-(`.%`&
MRX4&?(40#``!.@`%MM255G`%6-`%5)`#MCP0#X`&8`#JP![L394MLE4%3C`$
M*T"C,^`$6-!<?P7JVX(M?Y4&\",%8I`M8J`$5*,!7D#'9<`")WH"2W`%V&)>
MZZ6,!K$!.L`$4\""RI4M9L"*$3L7UI<G==4RVNF+J<@LT[0%37`P7S*)*AGF
M,2F<F!@EOA0&):`DLW2A%VJAM.B+T84%&]E7+2-57@!;O#F)%1H&[^0$=!(E
M6)41%V!/*Y.,1=,!](B7K<*%`T$%B>)+F\6XEROS!:8^[RED?0]0F]*2)C&@
M4RN04RJ@4[<EH!2J&Q=1`T(IB@.2$/-83EP0!1L`(AY`!?G.!580%D90,S,C
M,Q9S,4H0!HA23E]``0(Q`?42ED>"DF55E`A/3TAC`=68!2A?(TQ05AS3`YO;
M`!5P+F&R!2S7(Q\GL0XQ2YM8C*5KD;`HDQE@D"E)55&`*$,%`N9A`HM?'CG:
M$&?2)U_PPG)_B;,+*(+",1YO*$;)D`+AD+?IF!(9)5HPF\U1!H@U68CK@/^$
MSQ#B:2<,&18$L0(NE0550+Y>\OAD,@'7"2S%6'[C54Y58/9,,2,TT"Y:P@7_
M+A!WCRY:8@1!X`/;3S$_H"^/\O&GCY0/J932^<)O`0)?`)O`;P5GI596,`5L
M105<0/D9S1"1Z/I:D)@;00$``25+%BQ9K@!ID+"!#2X#LX!YD-""%BQ:+")4
MF#'ACRY7!E[!T,"!0@<C16I$.>)+%HM6OM@8.;('EBTT'6IQ2)`@SH<1%3II
MR-*(R8P8JCC\@D+C@R@%M70)DM$D"BX4=5+$DI6E08I@0J!D\$\L290)FP[L
MDM9+52U<N'1QRW;@%R\=-#)T",:D`Z<4EQ!%F17_ZQ2?"1_L8/+V2UK&C;O@
M%%R1"V"%#QYHP)`ALP;-&H)P<1JF<`.@`[4,16D4J=*,3+ERP:BQPI>"%9-4
ML)Q;]P,(E!N$'5NV<I6"#FM:O)(UZQ4M5I)380&X)%Z#>A72Z$BQRX^2&AT<
ML:*%.98=)Q^,;VDUYWK(XF.C]$T2"NB!8@`WH7_:MXLNR[]L$*F[!YZP"`O8
M`@QPI"1`HTB,"GR+3R'@_A&.)#`$XR(*&5YX08899I#!!AI>$"(*)'P@PH@F
MB-"HAOX\@B@C&<C8JBTF9!@A!!J4\**VAVX@R0O3+`HC"1(JT"!))9>T3*J$
M1OHARA^`H!*((*PTPL"*_ZI[X:2$G.AB*RN84"*)))IX@HLMKLKBR1=LD(&'
MHTS3T(8:9K#A@B>3Z*\B+;YH0H@HJ?RAAR"(L``LL2@4;J0'P+"(I2(@?+(!
M(`;:\J^3&!I/-))*$@(GYEABCJ+F*BI"(Q4>,[6+[BJ$52&/UF,I4E*WT"**
M"IQ,DZ6*QJNH.,AZ,(FI7T7U<<LN3L@(@J8*%,Q4GKQ2-+@*'RV."R(B-,D%
M3`FJ`H.8,F!A!7-?B/`!$GR00HPRQAC#"2!(B,G+!E:-U*)Z*]S+R83,+==<
M@5D@>(4C(]HW)A)<:&$%%E)H6.`54,#@`0<8(,J!$\JE@3B<N'`"!8%=D`#"
MR_]&"'B%AAM^8;2$)HSU`=HHXF*()TO::R06E!,5"I]P[C=6H;U\0`RM6.IB
MA$K+ZJ[IH9^&FFGOHL!4BR`8B#IJF&%]](J:"(H+KK?B\C58EE;(Z(;'JB)C
MWZR]<Z`#,FS=J8LMXL(;;\98>[MOH3-^]HHNWO.[PJVO%6,GG80]VK2!N+@"
MB:4;N`$GG&(LG&D?1BV;5H>*>YSOS$>W-Z:S6$+H5=(S.MR[)S?(0$D,+N",
M=@PVPT"#"GI+5[<((H0Z:*D>H"#)W)=$WO@-7%Z]<*(>0/("S7IKOEI&I9Z<
MLHP_):M[)X'/V<OMX?O;>[^!M_>DF-9O/OST;Q:N==?_&\`G'_OON1\??.ZY
M)I02&L@'/NSA-JF@#WT((DN]N!6U`S)-.K#RC?[N\<"LC<1^^"B=^`RW**'A
M+X#U\^#^ZH</)8QP?B=\7Z-0&#3M\0M[*2Q?T'1P#WS`PGMK:$,;8.@]X-$P
M']@#GOP22#_[R:*`.K!?/M80P'R$(A\TI"$^(C$2$Z##ATRT'SIVQ41CZ.^#
M2VC`/?"'#"SBXQQ;&.$3\Q&)A)B@'$GT8!8GP`3\^5""^$!'29:0Q`_>#QD`
MU%_&V%"_-O@0?U[$7T*8V(`]\I&/Z$@(":SHQ23BL0(F;(`@^NA%_1FC+$*$
M'_WJA\4HCI*$2=2A0F9!0S8T_\`$.8"+#FZ@`PK0@H9K`*021]*%^AEQA+@4
M21M`:((GA4)_.C3!#MR"@QWDP`*PT-\@`YB#FQDC@($`H/W:@(,<Y*`'Q]!F
M`.^A$38$4(<ZT%\LM/=!(N:#F@H!)SZP20(=+).;%)"%.4<YDA$&@@UK8`,;
MVK`#U4F(@Q#LXQ.C:#]LC(*8'M1(&P*HA@90(X"QP.$:`G%!-V03@[Y)8D9P
M8+]99&2)^="A-7JIAC:PX0^HO.!HN(!#,'I1$FW`(4X!NH,/LF\2^SMG`(W8
M`"[((A9><`!$\V$/?"!LESAU0@.P83]8X+0-?Q"A,.MG&#:$(A:P,"HMS&$_
M45A/A=\BV5\^2FJ^A$#Q4Q+-1RO1H3]SR,*NYI@K/M:05/MQ+R'ZPP=1D)@/
M=9YDD/AH@P/2@3]TP`*LZ$"'.2$AP0MZ\!XZ<$`DGHB/8L1"%M@`(07@NEDF
M`M4!$T@K8.U'@3!N51)B3"L?\:&#!IQC?XV-12S.,<E"/C$AU_C@,7(;"Q%B
M4R.@5-_2"#@YMF:DFSC`+'.7NT*X);<!.L!N#B+$S1TP,U'=RZX.<H`PDHA7
M!P_RUW5SH`,22&TDW.QF#G:%P/7J@*#-#5`WQ9N#]L;OH-4#<(`%/&`"!^]E
%BPH(`#L_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
